JBM (Healthcare) (HKSE:02161) Tariff Resilience Score: 0/10 (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02161 JBM (Healthcare) Ltd HKSE:02161
86 GF Score
Price HK$1.87
GF Value HK$2.09
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is JBM (Healthcare) Tariff Resilience Score?

JBM (Healthcare) has the Tariff Resilience Score of 0, which implies that the company might have .

JBM (Healthcare) has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes JBM (Healthcare) might have .

JBM (Healthcare)  (HKSE:02161) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

JBM (Healthcare) Tariff Resilience Score Related Terms

HKSE:02161
86GF Score
JBM (Healthcare) Ltd HKSE:02161
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is JBM (Healthcare) (HKSE:02161) Overvalued in 2026?

Based on GuruFocus' analysis, JBM (Healthcare) stock appears to be undervalued. The current stock price of HK$1.87 is trading 10.5% below its estimated GF Value™ of HK$2.09. GuruFocus considers JBM (Healthcare) to be Modestly Undervalued.

Key valuation signals for HKSE:02161:

  • Tariff Resilience Score: 0
  • GF Value™: HK$2.09 vs. price of HK$1.87 (10.5% below fair value)
  • GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JBM (Healthcare) Business Description

Address 108 Wai Yip Street, Units 808-811, 8 floor, C-Bons International Centre, Kwun Tong, Kowloon, Hong Kong, HKG
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
86GF Score

Get the complete analysis for HKSE:02161

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.87
Price
HK$2.09
GF Value